A2 BIO
LIVE

Serial Number

97980850

Owner

A2 Biotherapeutics, Inc.

Attorney

Joi A. White

First Use Date

May 1, 2023

Filing Date

Oct 14, 2021

Add to watchlist:

No watchlists yet
View on USPTO

A2 BIO Trademark

Serial Number: 97980850 • Registration: 8119042

A2 BIO is a trademark filed by A2 Biotherapeutics, Inc. on October 14, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

A2 Biotherapeutics, Inc. (10 trademarks)

Agoura Hills, CA 91301

Entity Type: 03

Trademark Details

Filing Date

October 14, 2021

Registration Date

January 27, 2026

First Use Anywhere

May 1, 2023

First Use in Commerce

May 1, 2023

Published for Opposition

April 4, 2023

Goods & Services

Therapeutics in the nature of cells, proteins and protein complexes for the treatment and prevention of cancer; biotherapeutics for the treatment and prevention of cancer; medicines for the treatment and prevention of cancer; pharmaceutical products for the treatment and prevention of cancer; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of cancer; therapeutic cells, therapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of cancer; therapeutics and cell therapies in the nature of cells, proteins and protein complexes for the treatment of cancer; engineered cell therapies in the nature of cells, proteins and protein complexes for medical purposes, namely, the treatment and prevention of cancer; engineered cell therapy platforms consisting of modified cells, cell receptors, proteins and protein complexes; cell platforms consisting of modified cells, cell receptors, proteins and protein complexes for the treatment and prevention of cancer; technology platforms for developing and engineering therapeutic cells, therapeutic proteins, therapeutic antibodies, therapeutics and cellular therapies for the treatment and prevention of cancer; platform for autologous and allogeneic cell manufacturing; therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer; gene therapy products, namely, genetically engineered tissues for transplant purposes;

Medical research services; pharmaceutical and biopharmaceutical research and development services; provision of medical and scientific research information in the fields of therapeutics, biotherapeutics, medicines, pharmaceuticals; identification and development of therapeutic targets for others for the treatment and prevention of cancer; development of therapeutics and cell therapies for treatment and prevention of cancer; research and development of therapeutics and cell therapies targeting targets lost for the treatment and prevention of cancer; biotechnology research, development, testing and analysis for the treatment of cancer; scientific research and development services; providing scientific information relating to treatment and prevention of cancer; research, development, engineering and testing services in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; medical laboratory services, namely, tissue material processing and analysis in the field of autologous and allogeneic biologic preparations for medical use; biotechnology laboratory services; scientific and medical laboratory services; genetic engineering services;

Custom manufacturing of therapeutics, biotherapeutics, medicines, and pharmaceuticals; manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of cancer; biomanufacturing for others, namely, manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of cancer using biological cells in the manufacturing process; cell therapy manufacturing for others; autologous and allogeneic cell manufacturing for others; manufacturing services for others in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; providing technical information in the field of pharmaceutical manufacturing; custom manufacturing and engineering of biological cells, cellular targets, proteins, and antibodies for others for treatment and prevention of cancer;

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jan 27, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Jan 27, 2026 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Jan 2, 2026 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Jan 2, 2026 CNPR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 11, 2025 EXRA
STATEMENT OF USE PROCESSING COMPLETE
Nov 10, 2025 SUPC
DIVISIONAL PROCESSING COMPLETE
Nov 10, 2025 DPCC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Nov 7, 2025 AITU
USE AMENDMENT FILED
May 30, 2025 IUAF
DIVISIONAL REQUEST RECEIVED
May 30, 2025 DRRR
TEAS REQUEST TO DIVIDE RECEIVED
May 30, 2025 ERTD
TEAS STATEMENT OF USE RECEIVED
May 30, 2025 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 20, 2025 EXRA
SOU EXTENSION 4 GRANTED
May 20, 2025 EX4G
SOU EXTENSION 4 FILED
May 19, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
May 19, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 7, 2024 EXRA
SOU EXTENSION 3 GRANTED
Nov 7, 2024 EX3G
SOU EXTENSION 3 FILED
Nov 7, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Nov 7, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 15, 2024 EXRA
SOU EXTENSION 2 GRANTED
May 14, 2024 EX2G
SOU EXTENSION 2 FILED
May 14, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
May 14, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 21, 2023 EXRA
SOU EXTENSION 1 GRANTED
Nov 17, 2023 EX1G
SOU EXTENSION 1 FILED
Nov 17, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 17, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 30, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 4, 2023 NPUB
PUBLISHED FOR OPPOSITION
Apr 4, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 15, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 25, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 24, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 23, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 23, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 22, 2022 GNRN
NON-FINAL ACTION E-MAILED
Jul 22, 2022 GNRT
NON-FINAL ACTION WRITTEN
Jul 22, 2022 CNRT
ASSIGNED TO EXAMINER
Jul 20, 2022 DOCK
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 13, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 13, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 13, 2022 REAP
NOTICE OF DESIGN SEARCH CODE E-MAILED
Nov 4, 2021 MDSM
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 3, 2021 NWOS
NEW APPLICATION ENTERED
Oct 18, 2021 NWAP